Grifols SA operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Grifols SA with three other
pharmaceutical manufacturers in Europe:
sales of 3.88 billion Euro [US$4.12 billion]
of which 100%
Lonza Group AG
(3.80 billion Swiss Francs [US$3.78 billion]
of which 57%
was Specialty Ingredients), and
based in Russia
(195.31 billion Russian Rubles [US$3.28 billion]
of which 81%
Grifols SA reported sales of 3.93 billion Euro (US$4.18 billion)
December of 2015.
increase of 17.3%
versus 2014, when the company's sales were 3.36 billion Euro.
Sales at Grifols SA have increased during each of the previous five years
(and since 2010, sales have increased a total of 297%).
Sales of Bioscience saw an increase
20.6% in 2015, from
2.51 billion Euro to 3.03 billion Euro.
Not all segments of Grifols SA experienced an increase in sales in 2015:
sales of Others/raw Materials fell 9.7% to 114.76 million Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).